Open access
133
Views
1
CrossRef citations to date
0
Altmetric
Original Research
Budget Impact of Belantamab Mafodotin (Belamaf) Adoption in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma in the United States
Anshul Shah1 Modelling and Simulation, Evidera, Waltham, MA, USACorrespondence[email protected]
, Jonathan C Tosh2 Modelling and Simulation, Evidera, London, UK
, Apoorva Ambavane2 Modelling and Simulation, Evidera, London, UK
, Andreas Nikolaou2 Modelling and Simulation, Evidera, London, UKhttps://orcid.org/0000-0002-5272-2369
, Cosmina Hogea3 Value Evidence and Outcomes, GlaxoSmithKline, Upper Providence, PA, USA
, Yevgeniy Samyshkin4 Value Evidence and Outcomes, GlaxoSmithKline, Brentford, UKhttps://orcid.org/0000-0003-3561-5585
, Boris Gorsh3 Value Evidence and Outcomes, GlaxoSmithKline, Upper Providence, PA, USA
, Eric M Maiese5 Value Evidence and Outcomes, GlaxoSmithKline, Philadelphia, PA, USA
& Feng Wang3 Value Evidence and Outcomes, GlaxoSmithKline, Upper Providence, PA, USA
show all
Pages 789-800
|
Published online: 10 Sep 2021
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.